EM2005C "Disease Modifying and Biologic Agent Use in COVID-19 Infection - A Rheumatologic Perspective" (IM GR-050120)
Purpose: to discuss the rationale for using existing Rheumatologic agents - disease modifying antirheumatic drugs (DMARDs) and biologic agents, in the treatment of those infected with the Coronavirus, and to discuss the safety, efficacy, potential toxicities and clinical trials for this drugs and where they may be used during the COVID-19 crisis.
UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.
At the conclusion of this activity, the participant should be able to:
- Be aware of the potential mechanistic benefits of antimalarial or JAK inhibitor therapy in COVID-19 infection
- Understand the similarities and treatment for the Cytokine Storm Syndrome and Macrophage Activation Syndrome
- Be aware of the potential use of corticosteroids, colchicine and other biologic in seriously infected COVID-19 patients
John J. Cush, M.D.
Professor of Internal Medicine
Division of Rheumatic Diseases
- 1.00 AMA